FDA grants Prescient Therapeutics (ASX:PTX) broad orphan drug status for PTX-100 cancer treatment
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its...
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its...
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for...
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US...
Clinical-stage oncology entity Prescient Therapeutics (ASX: PTX) -- focused on the development of novel and...
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage...
Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy...
COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by...
Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.